Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, ...

In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called anti-amyloid antibodies (anti-Aβ). These monoclonal anti-Aβs are proteins made ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

For the millions of Americans touched by Alzheimer’s disease, 2025 brought major advances in understanding of brain health ...

New research shows that blood from older animals can speed up Alzheimer’s-related changes in the brain, while young blood may ...

Despite reported slowing of progression, regulators said the evidence on the novel oral agent blarcamesine did not support a ...

A new study shows that components found in aged blood can speed up the buildup of amyloid proteins and alter behavior in an ...

Anavex Life Sciences Corp. ('Anavex” or the 'Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

B. Joy Snider's clinic focuses on early detection of memory issues, using biomarkers for precise Alzheimer's diagnosis and ...